“: We are reiterating our Overweight rating and $24 PT on Arrowhead Pharmaceuticals, following release of late-breaker abstracts for the Liver Meeting (AASLD) being held on San Francisco. Additional data from Arrowhead’s lead programs in hepatitis B virus (HBV) and alpha-1 antitrypsin (AAT) were made available further supporting activity of both compounds in chronic HBV patients and healthy volunteers, respectively. We believe these initial data add readthrough going into the meeting and further underscore Arrowhead’s ability to establish a platform RNAi company.”
According to TipRanks.com, Piros has currently no stars on a ranking scale of 0-5 stars, with an average return of -5.9% and a 41.2% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
Arrowhead Research has an analyst consensus of Strong Buy, with a price target consensus of $23.75, implying a 90.8% upside from current levels. In a report issued on October 4, Piper Jaffray also reiterated a Buy rating on the stock with a $25 price target.
The company has a one-year high of $22.39 and a one-year low of $3.01. Currently, Arrowhead Research has an average volume of 2.47M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arrowhead Pharmaceuticals, Inc. engages as a biopharmaceutical company developing targeted RNAi therapeutics. Its pipeline includes clinical programs in chronic hepatitis B virus and partner based programs in obesity and oncology. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Read More on ARWR: